BCHE and early-onset autosomal dominant Alzheimer disease: Physostigmine has patents related to inhibition of acetylcholinesterase and the treatment of AD (EP0296560), enhancing memory (US5177101, US2007197663), inhibition of butyrylcholinesterase and treatment of Alzheimer’s disease as well as dementia (EP0949920).